Dianthus Therapeutics, Inc. (DNTH)

Dianthus Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Revenue	2.83	6.42	0	0	0
Revenue Growth (YoY)	-55.96%	-	-	-	-
Gross Profit	2.83	6.42	0	0	0
Selling, General & Admin	18.16	6.74	27.93	28.09	23.76
Research & Development	32.84	29.38	46.77	50.62	59.21
Operating Expenses	51	36.12	74.69	78.7	82.97
Operating Income	-48.17	-29.71	-74.69	-78.7	-82.97
Other Expense / Income	-4.62	-1.23	-3.56	-3.77	-6.2
Pretax Income	-43.56	-28.48	-71.14	-74.94	-76.77
Net Income	-43.56	-28.48	-71.14	-74.94	-76.77
Shares Outstanding (Basic)	5	1	3	3	2
Shares Outstanding (Diluted)	5	1	3	3	2
Shares Change	489.48%	-74.54%	25.11%	18.66%	101.28%
EPS (Basic)	-8.45	-32.57	-20.64	-27.36	-33.12
EPS (Diluted)	-8.45	-32.57	-20.64	-27.36	-33.12
Free Cash Flow	-36.97	-29.21	-60.8	-64.42	-60.16
Free Cash Flow Per Share	-7.17	-33.41	-17.70	-23.47	-26.01
Gross Margin	100.00%	100.00%	-	-	-
Operating Margin	-1704.67%	-462.91%	-	-	-
Profit Margin	-1541.22%	-443.76%	-	-	-
Free Cash Flow Margin	-1308.24%	-455.18%	-	-	-
EBITDA	-43.2	-28.33	-69.12	-72.96	-74.93
EBITDA Margin	-1528.66%	-441.47%	-	-	-
Depreciation & Amortization	0.36	0.15	2.02	1.98	1.84
EBIT	-43.56	-28.48	-71.14	-74.94	-76.77
EBIT Margin	-1541.22%	-443.76%	-	-	-

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).